B-CELL LYMPHOID NEOPLASMS IN THE 5TH EDITION OF THE WHO CLASSIFICATION OF HEMATOLYMPHOID TUMORS (2022). 1. General principles of classification. Precursor B-cell neoplasms

Tumors of lymphoid and hematopoietic tissues are among the most prevalent malignancies. The tumors originating from lymphoid cells are of the utmost heterogeneity. The development of the generally accepted classifi ation sys- tem for this group of the malignancies became a priority task and its clinical implementation has been already advantageous. The in-depth insight into the pathogenesis of lymphoid neoplasms requires the continuous revision of the classification of these diseases. In 2022, World Health Organization specialists prepared the regular 5th issue of the Classification of Hematolymphoid Tumors representing a revision of the previous one (2017). The basic provisions of the new classification concerning B-cell lymphoid neoplasms are disclosed in this review composed of two parts. The review focuses on the principal changes as compared with the previous version of the classification. The first part of the review relates to two major categories such as tumor-like lesions with B-cell predominance and precursor B-cell neoplasms. The laboratory criteria important for the final diagnosis of the various nosological forms are discussed. Mature B-cell neoplasms, plasma cell neoplasms and other diseases with paraproteins will be presented in the next issue. the classification of these diseases. In 2022, World Health Organization specialists prepared the regular 5th issue of the Classification of Hematolymphoid Tumors representing a revision of the previous one (2017). The basic provisions of the new classification concerning B-cell lymphoid neoplasms are disclosed in this review composed of two parts. The review focuses on the principal changes as compared with the previous version of the classification. The first part of the review relates to two major categories such as tumor-like lesions with B-cell predominance and precursor B-cell neoplasms. The laboratory criteria important for the final diagnosis of the various nosological forms are discussed. Mature B-cell neoplasms, plasma cell neoplasms and other diseases with paraproteins will be presented in the next issue.

[1]  T. Szczepański,et al.  Commonly Assessed Markers in Childhood BCP-ALL Diagnostic Panels and Their Association with Genetic Aberrations and Outcome Prediction , 2022, Genes.

[2]  L. Staudt,et al.  The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. , 2022, Blood.

[3]  J. Smadbeck,et al.  Clinical utility of next generation sequencing to detect IGH/IL3 rearrangements [t(5;14)(q31.1;q32.1)] in B-lymphoblastic leukemia/lymphoma. , 2021, Annals of diagnostic pathology.

[4]  M. Maschan,et al.  Quantification of NG2‐positivity for the precise prediction of KMT2A gene rearrangements in childhood acute leukemia , 2020, Genes, chromosomes & cancer.

[5]  Ruth L. Seal,et al.  Guidelines for human gene nomenclature , 2020, Nature Genetics.

[6]  M. Lanzillotta,et al.  Advances in the diagnosis and management of IgG4 related disease , 2020, BMJ.

[7]  K. Ballen,et al.  MLL-Rearranged Acute Lymphoblastic Leukemia , 2020, Current Hematologic Malignancy Reports.

[8]  J. Bourquin,et al.  Targeting the oncogenic activity of TCF3-HLF in leukemia , 2020, Molecular & cellular oncology.

[9]  R. Stam,et al.  NUTM1 is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2 , 2019, Haematologica.

[10]  G. Paterakis,et al.  Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B‐acute lymphoblastic leukemia , 2019, International journal of laboratory hematology.

[11]  N. Popitsch,et al.  CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia , 2019, Haematologica.

[12]  A. Mattman,et al.  IgG4-related disease: what a hematologist needs to know , 2019, Haematologica.

[13]  W. Klapper,et al.  IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. , 2018, Blood.

[14]  B. Jagielska,et al.  Progressive transformation of germinal centers: an illustration of two clinical cases , 2018, Annals of Hematology.

[15]  M. Loh,et al.  Philadelphia chromosome-like acute lymphoblastic leukemia. , 2017, Blood.

[16]  J. Stuchly,et al.  ETV6/RUNX1‐like acute lymphoblastic leukemia: A novel B‐cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype , 2017, Genes, chromosomes & cancer.

[17]  J. Rossi,et al.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. , 2017, Blood.

[18]  K. Okamura,et al.  ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype , 2017, Haematologica.

[19]  Guido Marcucci,et al.  Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia , 2016, Nature Communications.

[20]  Jefte M. Drijvers,et al.  Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. , 2016, The Journal of allergy and clinical immunology.

[21]  B. Johansson,et al.  Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia , 2016, Nature Communications.

[22]  A. Moorman.  New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia , 2016, Haematologica.

[23]  R. Warnke,et al.  Immunoarchitectural patterns of progressive transformation of germinal centers with and without nodular lymphocyte-predominant Hodgkin lymphoma. , 2015, Human pathology.

[24]  C. Harrison,et al.  Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. , 2011, Blood.

[25]  N. Carter,et al.  Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.

[26]  N. Harris,et al.  Lymphoma‐Like Lesions of the Lower Female Genital Tract: A Report of 16 Cases , 1985, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[27]  K. Lennert,et al.  Concordance of the Kiel and Lukes‐Collins classifications of non‐Hodgkin's lymphomas , 1983, Histopathology.

[28]  T. Suchi,et al.  SOME PROBLEMS ON THE HISTOPATHOLOGICAL DIAGNOSIS OF NON‐HODGKIN'S MALIGNANT LYMPHOMA— A Proposal of a New Type— , 1979, Acta pathologica japonica.